|
|
|
Substance Name: Prazosin [INN:BAN]
RN: 19216-56-9
UNII: XM03YJ541D
InChIKey: IENZQIKPVFGBNW-UHFFFAOYSA-N
Note
- A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
Molecular Formula
- C19-H21-N5-O4
Molecular Weight
- 383.4059
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Structure Descriptors
- Toxicity
- Physical Properties
Classification Codes
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Antihypertensive Agents
- Antiviral (COVID-19)
- Cardiovascular Agents
- Drug / Therapeutic Agent
- Human Data
- Neurotransmitter Agents
- Reproductive Effect
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Regulatory Agencies (Superlist Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Prazosin
- Prazosin [INN:BAN]
MeSH Heading
- Prazosin
Synonyms
- 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
- 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
- 5-25-13-00365 (Beilstein Handbook Reference)
- BRN 0768345
- EINECS 242-885-8
- Furazosin
- Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-
- Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-
- Prazosin
- Prazosina
- Prazosina [INN-Spanish]
- Prazosine
- Prazosine [INN-French]
- Prazosinum
- Prazosinum [INN-Latin]
- Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-
- UNII-XM03YJ541D
Systematic Names
- Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-
- Prazosin
- Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-
Registry Numbers
CAS Registry Number
- 19216-56-9
FDA UNII
- XM03YJ541D
System Generated Number
- 0019216569
Structure Descriptors
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-NSmiles
COc1cc2nc(nc(N)Toxicity
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| human | TDLo | oral | 280ug/kg (0.28mg/kg) | VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | British Medical Journal. Vol. 2, Pg. 508, 1976. |
| human | TDLo | oral | 1260ug/kg (1.26mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) KIDNEY, URETER, AND BLADDER: OTHER CHANGES | British Medical Journal. Vol. 1, Pg. 622, 1978. |
| man | TDLo | oral | 1143ug/kg (1.143mg/kg) | VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Acta Medica Scandinavica. Vol. 213, Pg. 157, 1983. |
| mouse | LD50 | intravenous | > 400mg/kg (400mg/kg) | Russian Pharmacology and Toxicology Vol. 50, Pg. 182, 1987. | |
| mouse | LD50 | oral | > 4gm/kg (4000mg/kg) | Bollettino Chimico Farmaceutico. Vol. 128, Pg. 129, 1989. | |
| rat | LD | oral | > 3gm/kg (3000mg/kg) | United States Patent Document. Vol. #4734418, | |
| women | TDLo | oral | 20ug/kg (0.02mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Annals of Internal Medicine. Vol. 97, Pg. 455, 1982. |
Physical Properties
| Physical Property | Value | Units | Temp (deg C) | Source |
|---|---|---|---|---|
| Melting Point | 279 | deg C | EXP | |
| log P (octanol-water) | 1.280 | (none) | EST | |
| Atmospheric OH Rate Constant | 2.84E-10 | cm3/molecule-sec | 25 | EST |
Physical property data is provided to ChemIDplus by SRC, Inc.